Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L.

J Natl Cancer Inst. 2013 Apr 3;105(7):469-74. doi: 10.1093/jnci/djt032. Epub 2013 Mar 13.

2.

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L.

JAMA. 2014 Feb 12;311(6):597-603. doi: 10.1001/jama.2014.95.

PMID:
24519299
3.

Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.

Dominiak-Felden G, Gobbo C, Simondon F.

PLoS One. 2015 Jul 6;10(7):e0132404. doi: 10.1371/journal.pone.0132404. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0148665.

4.

Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.

Blomberg M, Dehlendorff C, Sand C, Kjaer SK.

Clin Infect Dis. 2015 Sep 1;61(5):676-82. doi: 10.1093/cid/civ364. Epub 2015 May 5.

PMID:
25944340
5.

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK.

Lancet Infect Dis. 2011 Jan;11(1):39-44. doi: 10.1016/S1473-3099(10)70225-5. Epub 2010 Nov 8.

PMID:
21067976
6.

Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, Simard JF.

J Infect Dis. 2012 Sep 15;206(6):860-6. doi: 10.1093/infdis/jis405. Epub 2012 Jul 18.

PMID:
22815381
7.

Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.

Blomberg M, Dehlendorff C, Munk C, Kjaer SK.

Clin Infect Dis. 2013 Oct;57(7):929-34. doi: 10.1093/cid/cit436. Epub 2013 Jun 26.

PMID:
23804192
8.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27.

PMID:
23104323
9.

Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.

Lurie S, Mizrachi Y, Chodick G, Katz R, Schejter E.

Gynecol Oncol. 2017 Aug;146(2):299-304. doi: 10.1016/j.ygyno.2017.06.001. Epub 2017 Jun 8.

PMID:
28602548
11.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

12.
13.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

14.

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J.

BMC Cancer. 2013 Jan 8;13:10. doi: 10.1186/1471-2407-13-10.

15.

Health and economic implications of HPV vaccination in the United States.

Kim JJ, Goldie SJ.

N Engl J Med. 2008 Aug 21;359(8):821-32. doi: 10.1056/NEJMsa0707052.

16.

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.

Lancet Infect Dis. 2015 May;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4. Epub 2015 Mar 3. Review.

17.

Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.

Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW.

PLoS One. 2013 Nov 18;8(11):e80639. doi: 10.1371/journal.pone.0080639. eCollection 2013.

18.
19.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

20.

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.

Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.

PMID:
19493565

Supplemental Content

Support Center